Goldman Sachs Maintains Buy on NeoGenomics, Lowers Price Target to $17
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Matthew Sykes has maintained a 'Buy' rating on NeoGenomics (NASDAQ:NEO) but lowered the price target from $19 to $17.
October 23, 2023 | 1:00 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Goldman Sachs has maintained a 'Buy' rating on NeoGenomics but lowered the price target from $19 to $17.
The news is directly related to NeoGenomics and is likely to influence investor sentiment. While the 'Buy' rating is maintained, the lowering of the price target may indicate a potential downside, which could lead to mixed reactions in the market.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100